Skip to Content

Triferic Approval History

  • FDA approved: Yes (First approved January 23rd, 2015)
  • Brand name: Triferic
  • Generic name: ferric pyrophosphate citrate
  • Dosage form: Solution
  • Company: Rockwell Medical, Inc.
  • Treatment for: Anemia Associated with Chronic Renal Failure

Triferic (ferric pyrophosphate citrate) is an iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.

Development History and FDA Approval Process for Triferic

Jan 26, 2015Approval FDA Approves Triferic for Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients
May 28, 2014Rockwell Medical Announces FDA Acceptance for Filing of Triferic New Drug Application
Mar 24, 2014Rockwell Medical Submits NDA for Triferic

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.